JP7566766B2 - 抗Vβ17/抗CD123二重特異性抗体 - Google Patents

抗Vβ17/抗CD123二重特異性抗体 Download PDF

Info

Publication number
JP7566766B2
JP7566766B2 JP2021553382A JP2021553382A JP7566766B2 JP 7566766 B2 JP7566766 B2 JP 7566766B2 JP 2021553382 A JP2021553382 A JP 2021553382A JP 2021553382 A JP2021553382 A JP 2021553382A JP 7566766 B2 JP7566766 B2 JP 7566766B2
Authority
JP
Japan
Prior art keywords
antigen
seq
binding fragment
bispecific antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021553382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523442A5 (cg-RX-API-DMAC7.html
JP2022523442A (ja
Inventor
ガネーシャン,ラージクマール
グレワル,イクバル,エス.
セプルベダ,マニュエル,アレハンドロ
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2022523442A publication Critical patent/JP2022523442A/ja
Publication of JP2022523442A5 publication Critical patent/JP2022523442A5/ja
Priority to JP2024135000A priority Critical patent/JP2024170426A/ja
Application granted granted Critical
Publication of JP7566766B2 publication Critical patent/JP7566766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021553382A 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体 Active JP7566766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135000A JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
US62/816,464 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135000A Division JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022523442A JP2022523442A (ja) 2022-04-22
JP2022523442A5 JP2022523442A5 (cg-RX-API-DMAC7.html) 2023-03-17
JP7566766B2 true JP7566766B2 (ja) 2024-10-15

Family

ID=71670296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553382A Active JP7566766B2 (ja) 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Country Status (12)

Country Link
US (2) US12264197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3937977A2 (cg-RX-API-DMAC7.html)
JP (2) JP7566766B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210138033A (cg-RX-API-DMAC7.html)
CN (2) CN119954959A (cg-RX-API-DMAC7.html)
AU (1) AU2020235475B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017801A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132916A1 (cg-RX-API-DMAC7.html)
IL (1) IL286147A (cg-RX-API-DMAC7.html)
MA (1) MA55305A (cg-RX-API-DMAC7.html)
MX (1) MX2021010857A (cg-RX-API-DMAC7.html)
WO (1) WO2020183245A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス,インコーポレーテッド NKp30に結合する抗体分子およびその使用
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
IL300505A (en) * 2020-08-10 2023-04-01 Janssen Biotech Inc Materials and methods for the production of biologically engineered virus-specific lymphocytes
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
UY39415A (es) * 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4426734A1 (en) * 2021-11-01 2024-09-11 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
AU2023217968A1 (en) * 2022-02-09 2024-09-26 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
AU2024217296A1 (en) * 2023-02-09 2025-09-25 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2013537418A (ja) 2010-08-17 2013-10-03 シーエスエル、リミテッド ヒト化抗インターロイキン3レセプターα鎖抗体
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ.ベー. Cd123結合剤及びその使用
JP2018527954A (ja) 2015-09-15 2018-09-27 アダプティミューネ リミテッドAdaptimmune Limited Tcrライブラリ

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
FR2681875A1 (fr) 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6084087A (en) * 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
US9790274B2 (en) 2013-03-14 2017-10-17 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
US10556959B2 (en) 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
WO2016167306A1 (ja) 2015-04-16 2016-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトNotch4抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
JP7252627B2 (ja) * 2016-12-15 2023-04-05 デューク ユニバーシティ 制御性b10細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7700039B2 (ja) 2019-01-04 2025-06-30 マレンゴ・セラピューティクス,インコーポレーテッド 抗tcr抗体分子およびその使用
CN119954959A (zh) 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
CA3143995A1 (en) 2019-06-21 2020-12-24 Single Cell Technology, Inc. Anti-tigit antibodies
WO2021064671A1 (en) 2019-10-03 2021-04-08 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
CA3173268A1 (en) 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
UY39415A (es) 2020-09-11 2022-03-31 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadenas beta
IL301242A (en) 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518753A (ja) 2003-02-20 2006-08-17 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2013537418A (ja) 2010-08-17 2013-10-03 シーエスエル、リミテッド ヒト化抗インターロイキン3レセプターα鎖抗体
JP2017529838A (ja) 2014-09-05 2017-10-12 ヤンセン ファーマシューティカ エヌ.ベー. Cd123結合剤及びその使用
JP2018527954A (ja) 2015-09-15 2018-09-27 アダプティミューネ リミテッドAdaptimmune Limited Tcrライブラリ

Also Published As

Publication number Publication date
AU2020235475A1 (en) 2021-09-30
BR112021017801A2 (pt) 2022-01-18
CN113874400B (zh) 2025-02-07
MX2021010857A (es) 2021-12-15
WO2020183245A2 (en) 2020-09-17
CN119954959A (zh) 2025-05-09
US20250257132A1 (en) 2025-08-14
AU2020235475B2 (en) 2026-07-16
IL286147A (en) 2021-10-31
US12264197B2 (en) 2025-04-01
WO2020183245A3 (en) 2020-12-03
KR20210138033A (ko) 2021-11-18
MA55305A (fr) 2022-01-19
US20220127359A1 (en) 2022-04-28
CN113874400A (zh) 2021-12-31
JP2024170426A (ja) 2024-12-10
JP2022523442A (ja) 2022-04-22
CA3132916A1 (en) 2020-09-17
EP3937977A2 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
US20250257132A1 (en) ANTI-Vbeta17/ANTI-CD123 BISPECIFIC ANTIBODIES
JP7686571B2 (ja) T細胞媒介性免疫を調節するための材料及び方法
JP7862361B2 (ja) Hla-g抗原結合ドメインを含むタンパク質及びそれらの使用
AU2022223152A1 (en) Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
RS66901B1 (sr) Anti-cd3 antitela i njihova upotreba
KR20160029128A (ko) 이중특이적 cd3 및 cd19 항원 결합 구조체
KR20200085828A (ko) 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
TW202231292A (zh) 用於調節分化簇iv及/或viii的經生物工程改造之t細胞介導之免疫力、材料、及其他方法
TW202210510A (zh) 包含cd3抗原結合域之蛋白質及其用途
CN116390950A (zh) 用于调节δγ链介导的免疫的组合物和方法
US12448449B2 (en) Immune targeting molecules and uses thereof
CA3219606A1 (en) Heterodimeric fc domain antibodies
JP2024507937A (ja) Cd123及びガンマデルタt細胞受容体に結合する抗体
KR20240111783A (ko) 면역 반응을 위한 강화된 다중특이성 결합제를 포함하는 조성물
WO2024166047A1 (en) Anti-v beta 17/anti-cd123 bispecific antibodies
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
CN118742566A (zh) 包含用于免疫应答的增强型多特异性结合剂的组合物
WO2026073840A1 (en) Antibodies that bind to cd3 and uses therefor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241002

R150 Certificate of patent or registration of utility model

Ref document number: 7566766

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150